Search clinical trials for: Pomalyst
Total 112 results
-
CelgeneNot yet recruitingMultiple MyelomaChina, Australia, United States, Argentina, Austria, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Greece, Hungary, India, Ireland, Italy, Japan, Korea, Republic of, Norway, Portugal, Romania, Spain, Sweden, Switzerland, Turkey, United Kingdom
-
Janssen Research & Development, LLCRecruitingRelapsed or Refractory Multiple MyelomaGermany, Korea, Republic of, Italy, France, Japan, Israel, Belgium, Denmark, Sweden, China, Spain, Czechia, Poland, Australia, Netherlands, Argentina, Canada, United Kingdom, Greece, Brazil, India
-
University of ChicagoGlaxoSmithKline; AmgenRecruitingMultiple Myeloma | Relapse Multiple MyelomaUnited States
-
Regeneron PharmaceuticalsRecruitingRelapsed Refractory Multiple Myeloma (RRMM)Canada, United States, Korea, Republic of, Israel, Taiwan, Spain, Australia, Brazil, France, United Kingdom, Poland, Singapore, Italy
-
CelgeneRecruitingRelapsed or Refractory Multiple MyelomaUnited States, Australia, Italy, China, Spain, Germany, Romania, Korea, Republic of, Japan, United Kingdom, Czechia, Finland, France, Greece, Argentina, Belgium, Austria, Portugal, Israel, Poland, Brazil, Turkey, Canada, Ireland, New Zealand and more
-
Rajshekhar Chakraborty, MDGenentech, Inc.RecruitingAL AmyloidosisUnited States
-
SanofiRecruitingPlasma Cell Myeloma RecurrentUnited States, Argentina, Australia, Brazil, Canada, Chile, China, Czechia, France, Germany, Greece, Hungary, Italy, Japan, Norway, Poland, Spain, Sweden, Taiwan, Turkey, United Kingdom
-
LanZhou UniversityBeijing Health Alliance Charitable FoundationRecruitingMultiple MyelomaChina
-
Emory UniversityNational Cancer Institute (NCI); GlaxoSmithKlineRecruitingPlasma Cell MyelomaUnited States
-
Regeneron PharmaceuticalsRecruitingMultiple MyelomaUnited States, Spain, France, Greece
-
Dana-Farber Cancer InstituteBristol-Myers SquibbNot yet recruitingMultiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma, RefractoryUnited States
-
PfizerRecruitingMultiple MyelomaChina, Korea, Republic of, Taiwan, United States, Australia, Japan, Spain, Czechia, United Kingdom, Canada, Germany, New Zealand, Italy, France, Sweden, Poland, Netherlands, Austria, Mexico, Finland, Argentina, Belgium, Brazil, Greece, ... and more
-
Juan DuRecruitingMultiple MyelomaChina
-
University of WashingtonGenzyme, a Sanofi CompanyRecruitingRefractory Multiple Myeloma | Recurrent Multiple MyelomaUnited States
-
Medical College of WisconsinRecruitingMultiple MyelomaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Acute Myeloid Leukemia With Multilineage Dysplasia | Acute Myeloid Leukemia Post Cytotoxic TherapyUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingRefractory Multiple Myeloma | Recurrent Multiple MyelomaUnited States
-
Hackensack Meridian HealthKaryopharm Therapeutics IncRecruitingMultiple MyelomaUnited States
-
SanofiRecruitingPlasma Cell Myeloma RefractoryFrance, Australia, Greece, Italy, Norway, United States, Portugal, Puerto Rico, Germany
-
National Cancer Institute (NCI)Recruiting
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRefractory Plasma Cell Myeloma | Recurrent Plasma Cell MyelomaUnited States
-
SanofiRecruitingPlasma Cell MyelomaGermany, United States, Argentina, China, France, Hong Kong, Italy, Japan, Puerto Rico, Spain, Switzerland, United Arab Emirates, United Kingdom, Austria, Belgium, Netherlands, Taiwan
-
Andrew Yee, MDJanssen Research & Development, LLC; AmgenRecruitingMultiple Myeloma | Refractory Multiple Myeloma | Relapse | Multiple Myeloma in RelapseUnited States
-
Omar Nadeem, MDTakedaRecruitingMultiple Myeloma | Multiple Myeloma in RelapseUnited States
-
Multiple Myeloma Research ConsortiumEli Lilly and Company; GlaxoSmithKline; AbbVie; Takeda; Genentech, Inc.; Celgene Corporation and other collaboratorsRecruitingRelapsed Refractory Multiple MyelomaUnited States
-
Canadian Myeloma Research GroupGlaxoSmithKlineRecruitingRelapsed and/or Refractory Multiple MyelomaCanada
-
CelgeneRecruitingMultiple MyelomaKorea, Republic of
-
University of ChicagoNational Cancer Institute (NCI); Multiple Myeloma Research FoundationRecruitingMultiple MyelomaUnited States, Canada
-
AmgenActive, not recruitingRelapsed or Refractory Multiple MyelomaUnited States, Spain, Germany, France, Italy, Denmark, Greece, Estonia
-
AbbVieRoche-GenentechActive, not recruitingMultiple MyelomaUnited States, Australia, Canada, China, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Russian Federation, Singapore, Spain, Sweden, Turkey, Ukraine, United Kingdom
-
Karyopharm Therapeutics IncBristol-Myers SquibbActive, not recruitingMultiple MyelomaUnited States, Canada
-
University of California, San DiegoTakeda; Celgene; Janssen, LPActive, not recruitingRelapsed/Refractory Multiple MyelomaUnited States
-
SanofiCompletedMultiple MyelomaFrance, Spain, Belgium, Australia, United States, Japan
-
The Cleveland ClinicRTI InternationalCompletedTelangiectasia, Hereditary HemorrhagicUnited States
-
Massachusetts General HospitalMultiple Myeloma Research ConsortiumActive, not recruitingMultiple MyelomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingRefractory Plasma Cell MyelomaUnited States
-
CelgeneCompletedCentral Nervous System Neoplasms | MedulloblastomaUnited States, Italy, France, Spain, United Kingdom
-
Massachusetts General HospitalBristol-Myers Squibb; Celgene; Multiple Myeloma Research ConsortiumActive, not recruitingMultiple MyelomaUnited States
-
Bristol-Myers SquibbAbbVieActive, not recruitingMultiple MyelomaUnited States, Canada, Australia, Poland, Italy, Belgium, Spain, Japan, Greece, Hungary, Romania, Turkey, United Kingdom
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell MyelomaUnited States
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH); AmgenActive, not recruitingPlasma Cell MyelomaUnited States
-
Mayo ClinicActive, not recruitingPlasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Smoldering Plasma Cell MyelomaUnited States
-
Cristina GasparettoCelgeneActive, not recruiting
-
CelgeneActive, not recruitingMultiple MyelomaUnited States
-
Oncopeptides ABTerminatedMultiple MyelomaUnited States, Austria, Belgium, Czechia, Denmark, Estonia, France, Greece, Hungary, Israel, Italy, Korea, Republic of, Lithuania, Netherlands, Norway, Poland, Romania, Russian Federation, Spain, Taiwan, United Kingdom
-
Hackensack Meridian HealthJanssen, LPTerminatedMultiple MyelomaUnited States
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); University of California, Los Angeles; Montefiore... and other collaboratorsActive, not recruitingHuman Immunodeficiency Virus 1 Positive | Skin Kaposi SarcomaUganda, Kenya, Malawi
-
Washington University School of MedicineBristol-Myers Squibb; CelgeneActive, not recruitingMultiple Myeloma in RelapseUnited States, Canada
-
OHSU Knight Cancer InstituteSanofi; Oregon Health and Science UniversityActive, not recruitingRefractory Plasma Cell Myeloma | Recurrent Plasma Cell MyelomaUnited States